Pacira Pharma (PCRX) Tops Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharma (PCRX) Tops Q4 EPS by 9c

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

February 24, 2022 8:00 AM EST

Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million More than 10 million patients have received EXPAREL since launch Conference call today at 8:30 a.m. ET

TAMPA, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2021.

The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in... More